Controlled release of bioactive recombinant human growth hormone from PLGA microparticles

Journal of Microencapsulation

Volumn 27, Issue 6, 2010, Pages 552-560

  Rafi, Md ^a   Singh, Surinder M ^a   Kanchan, Vibhu ^a   Anish, C K ^a   Panda, Amulya K ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

Bioactivity; Controlled delivery; Human growth hormone; Microparticle; Protein stability

Indexed keywords

BICARBONATE; DICHLOROMETHANE; HUMAN GROWTH HORMONE; POLYGLACTIN; SUCROSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DEGRADATION; DENATURATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG RELEASE; EMULSION; ENCAPSULATION; FREEZE DRYING; IN VITRO STUDY; NONHUMAN; RAT; SINGLE DRUG DOSE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; FREEZE DRYING; HUMAN GROWTH HORMONE; HUMANS; LACTIC ACID; POLYGLYCOLIC ACID; PROTEIN DENATURATION; PROTEIN STABILITY; RATS; RATS, WISTAR; RECOMBINANT PROTEINS;

EID: 77955439513     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2010.489974     Document Type: Article

References (37)

1. Bilati U, Allemann E, Doelker E. 2005. Strategic approach for overcoming peptide and protein instability within biodegradable nano-and microparticles. Eur J Pharm Biopharm 59:365-388.
2. Cheng YH, Dyer AM, Jabbal-Gill I, Hinchcliffe M, Nankervis R, Smith A, Watts P. 2005. Intranasal delivery of recombinant human growth hormone (somatropin) in sheep using chitosan-based powder formulations. Eur J Pharm Sci 26:9-15.
3. Cleland JL, Daughtery A, Mrsny R. 2001. Emerging protein delivery methods. Curr Opin Biotechnol 12:212-219.
4. Cleland JL, Johnson OL, Putney S, Jones AJS. 1997. Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development. Adv Drug Deliv Rev 28:71-84.
5. Fu K, Pack DW, Klibanov AM, Langer R. 2000. Visual evidence of acidic environment within degrading poly (lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res 17:100-106.
6. Giteau A, Venier-Julienne MC, Aubert-Pouessel A, Benoit JP. 2008. How to achieve sustained and complete protein release from PLGA based microparticles. Int J Pharma 350:14-26.
7. Hahn SK, Kim SJ, Kim MJ, Kim DH. 2004. Characterization and in vivo study of sustained release formulation of human growth hormone using sodium hyaluronate. Pharm Res 21:1374-1381.
8. Johnson OL, Jaworowicz W, Cleland JL, Bailey L, Charnis M, Duenas E, Wu C, Shepard D, Magil S, Last T, et al. 1997. The stabilization and encapsulation of human growth hormone into biodegradable microparticles. Pharm Res 14:730-735.
9. Juul A, Jorgensen JO, Christiansen JS, Muller J, Skakkeboek NE. 1995. Metabolic effects of GH: A rationale for continued GH treatment of GH-deficient adults after cessation of linear growth. Horm Res 44:64-72.
10. Katakam M, Ravis WR, Golden DL, Banga AK. 1997. Controlled release of human growth hormone following subcutaneous administration in dogs. Int J Pharm 152:53-58. (Pubitemid 27254961)
11. Katare YK, Muthukukaran T, Panda AK. 2005. Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles. Int J Pharm 301:149-160.
12. Kim SJ, Hahn SK, Kim MJ, Kim DH, Lee YP. 2005. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. J Control Release 104:323-335.
13. Kim HK, Park TG. 2004. Comparative study on sustained release of human growth hormone from semi-crystalline poly (L-lactic acid) and amorphous poly (D,L-lactic-co-glycolic acid) microspheres: Morphological effect on protein release. J Control Release 98:115-125.
14. Kumar TR, Soppimath K, Nachaegari SK. 2006. Novel delivery technologies for protein and peptide therapeutics. Curr Pharm Biotechnol 7:261-276.
15. Lee HJ, Riley G, Johnson O, Cleland JL, Kim N, Charnis M, Bailey L, Duenas E, Shahzamani A, Marian M, et al. 1997. In vivo characterization of sustained-release formulations of human growth hormone. J Pharmacol Exp Ther 281:1431-1439.
16. Leitner VM, Guggi D, Krauland AH, Bernkop-Schnürch A. 2004. Nasal delivery of human growth hormone: In vitro and in vivo evaluation of a thiomer/glutathione microparticulate delivery system. J Control Release 100:87-95.
17. Levin G, Gershonowitz A, Sacks H, Stern M, Sherman A, Rudaev S, Zivin I, Phillip M. 2005. Transdermal delivery of human growth hormone through RF-microchannels. Pharm Res 22:550-555.
18. Li X, Zhang Y, Yan R. 2000. Influence of process parameters on the protein stability encapsulated in poly-D,L-lactide-poly (ethylene glycol) micro-particles. J Control Release 68:41-52.
19. Mehls O, Tonshoff B, Haffner D, Wuhl E, Schaefer F. 1994. The use of recombinant human growth hormone in short children with chronic renal failure. J Pediatr Endocrinol 7:107-113. (Pubitemid 24144292)
20. Nihant N, Schugens C, Grandfils C, Jerome R, Teyssie P. 1994. Polylactide microparticles prepared by double emulsion/evaporation technique. I. Effect of primary emulsion stability. Pharm Res 10:1479-1484.
21. Patra AK, Mukhopadhyay R, Mukhija R, Krishnan A, Garg LC, Panda AK. 2000. Optimization of inclusion body solubilization and renaturation of recombinant human growth hormone from E. coli. Protein Expr Purif 18:182-192.
22. Perez C, Griebenow K. 2001. Improved activity and stability of lysozyme at the water/CH2Cl2 interface: Enzyme unfolding and aggregation and its prevention by polyols. J Pharm Pharmacol 53:1217-1226.
23. Raghuvanshi RS, Goyal S, Singh Om, Panda AK. 1998. Stabilization of dichloromethane-induced protein denaturation during microencapsulation. Pharm Dev Technol 3:269-276.
24. Ranke MB. 1995. Growth hormone therapy in Turner syndrome. Analysis of long-term results. Horm Res 44:35-41.
25. Sah H. 1999. Protein instability toward organic solvent/water emulsification: Implications for protein microencapsulation into microparticles. J Pharm Sci Technol 53:3-10.
26. Schwendeman SP. 2002. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit Rev Ther Drug Carrier Syst 19:73-98.
27. Sinha VR, Trehan A. 2003. Biodegradable microsphere for protein delivery. J Controlled Release 90:261-280.
28. Srinivasan C, Katare YK, Muthukumaran T, Panda AK. 2005. Effect of additives on encapsulation efficiency, stability and bioactivity of entrapped lysozyme from biodegradable polymer particles. J. Microencapsul 22:127-138.
29. Takada S, Yamagata Y, Misaki M, Taira K, Kurokawa T. 2003. Sustained release of human growth hormone from microcapsules prepared by a solvent evaporation technique. J Control Release 88:229-242.
30. Tamber H, Johansen P, Merkle HP, Gander B. 2005. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv Drug Delivery Rev 57:357-376.
31. Vance ML, Mauras N. 1999. Growth hormone therapy in adults and children. N Engl J Med 341:1206-1216.
32. Vlugt-Wensink KDF, Meijer YJ, Steenbergen MJV, Verrijk R, Jiskoot W, Crommelin DJA, Hennink WE. 2007. Effect of excipients on the encapsulation efficiency and release of human growth hormone from dextran microsphere. Eur J Pharm Biopharm 67:589-596.
33. Weert M, Hennink WE, Jiskoot W. 2000. Protein instability in poly (lactic-co-glycolic acid) microparticles. Pharm Res 17:1159-1167.
34. Wei G, Lu LF, Lu WY. 2007. Stabilization of recombinant human growth hormone against emulsification-induced aggregation by Pluronic surfactants during microencapsulation. Int J Pharm 338:125-132.
35. Weinroth SE, Parenti DM, Simon GL. 1995. Wasting syndrome in AIDS: Pathophysiologic mechanisms and therapeutic approaches. Infect Agents Dis 4:76-94.
36. Zhu G, Mallery SR, Schwendeman SP. 2000. Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide). Nat Biotechnol 18:52-57.
37. Zolnik BS, Burgess DJ. 2007. Effect of acidic pH on PLGA microsphere degradation and release. J Control Release 122:338-344.